DNA methylation markers detected in blood, stool, urine, and tissue in colorectal cancer: a systematic review of paired samples
暂无分享,去创建一个
[1] D. Moher,et al. Steps toward more complete reporting of systematic reviews of diagnostic test accuracy: Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy (PRISMA-DTA) , 2019, Systematic Reviews.
[2] N. Pavlidis,et al. The Developing Story of Predictive Biomarkers in Colorectal Cancer , 2019, Journal of personalized medicine.
[3] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[4] A. Gavin,et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.
[5] S. Bagaria,et al. Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction , 2018, Front. Oncol..
[6] M. W. Ørntoft,et al. Review of Blood‐Based Colorectal Cancer Screening: How Far Are Circulating Cell‐Free DNA Methylation Markers From Clinical Implementation? , 2018, Clinical colorectal cancer.
[7] David H. Murray,et al. Circulating tumour DNA for monitoring colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection , 2018, Clinical Epigenetics.
[8] L. Pan,et al. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer , 2018, Disease markers.
[9] C. Yi,et al. Liquid biopsies: DNA methylation analyses in circulating cell-free DNA. , 2018, Journal of genetics and genomics = Yi chuan xue bao.
[10] P. Marcato,et al. Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum , 2018, Cancers.
[11] A. El-Shal,et al. Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients. , 2018, Gene.
[12] E. Sakhinia,et al. BMP3 promoter hypermethylation in plasma-derived cell-free DNA in colorectal cancer patients , 2018, Genes & Genomics.
[13] A. Goel,et al. Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives , 2017, Seminars in cancer biology.
[14] A. Kalmár,et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples , 2017, Epigenetics.
[15] P. Madsen,et al. Hypermethylated DNA, a circulating biomarker for colorectal cancer detection , 2017, PloS one.
[16] Haiping Wu,et al. Digital quantification of gene methylation in stool DNA by emulsion-PCR coupled with hydrogel immobilized bead-array. , 2017, Biosensors & bioelectronics.
[17] M. van Engeland,et al. Details matter: the role of genomic location and assay standardization in DNA methylation analyses. , 2017, Epigenomics.
[18] E. Jamal,et al. Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates. , 2017, Experimental and molecular pathology.
[19] M. Houshmand,et al. Assessment of Bone Morphogenetic Protein 3 Methylation in Iranian Patients with Colorectal Cancer , 2017, Middle East journal of digestive diseases.
[20] Massoud Saidijam,et al. Detection of SPG20 gene promoter-methylated DNA, as a novel epigenetic biomarker, in plasma for colorectal cancer diagnosis using the MethyLight method. , 2017, Oncology letters.
[21] J. Ioannidis,et al. Waste, Leaks, and Failures in the Biomarker Pipeline. , 2017, Clinical chemistry.
[22] Rui Zhang,et al. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer , 2017, Oncotarget.
[23] M. Agostini,et al. Diagnostic and prognostic role of cell‐free DNA testing for colorectal cancer patients , 2017, International journal of cancer.
[24] H. Prenen,et al. Current and future biomarkers in the treatment of colorectal cancer , 2017, Acta clinica Belgica.
[25] N. Rosenfeld,et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.
[26] Yvette N. Lamb,et al. Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer , 2017, Molecular Diagnosis & Therapy.
[27] S. Hines,et al. The short-term impact of colorectal cancer treatment on physical activity, functional status and quality of life: a systematic review , 2017, JBI database of systematic reviews and implementation reports.
[28] Lawrence C. LaPointe,et al. Evaluation of Methylation Biomarkers for Detection of Circulating Tumor DNA and Application to Colorectal Cancer , 2016, Genes.
[29] P. Mokarram,et al. Epigenetic biomarkers in colorectal cancer: premises and prospects , 2016, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[30] P. Madsen,et al. Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review , 2016, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[31] Y. Jung,et al. Field Cancerization in Sporadic Colon Cancer , 2016, Gut and liver.
[32] Ajay Goel,et al. DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer. , 2016, Epigenomics.
[33] J. Ji,et al. OSMR and SEPT9: promising biomarkers for detection of colorectal cancer based on blood-based tests , 2016 .
[34] William M. Grady,et al. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. , 2015, Gastroenterology.
[35] G. Lippi,et al. Comparison of Genetic and Epigenetic Alterations of Primary Tumors and Matched Plasma Samples in Patients with Colorectal Cancer , 2015, PloS one.
[36] P. Jin,et al. Performance of a second‐generation methylated SEPT9 test in detecting colorectal neoplasm , 2015, Journal of gastroenterology and hepatology.
[37] U. Gottschalk,et al. Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: putative risk markers for colitis-associated cancer , 2015, Journal of Cancer Research and Clinical Oncology.
[38] Masao Tanaka,et al. Comparative detection of aberrantly methylated DNA in preoperative and postoperative stool from patients with colorectal cancers , 2015, The International journal of biological markers.
[39] Weiwei Dong,et al. Quantitative detection of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer , 2014, Oncology letters.
[40] A. Kalmár,et al. Detection of Methylated Septin 9 in Tissue and Plasma of Colorectal Patients with Neoplasia and the Relationship to the Amount of Circulating Cell-Free DNA , 2014, PloS one.
[41] M. Hernán,et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. , 2014, JAMA.
[42] K. Hibi,et al. Serum vimentin methylation as a potential marker for colorectal cancer. , 2014, Anticancer research.
[43] A. Amiot,et al. The Detection of the Methylated Wif-1 Gene Is More Accurate than a Fecal Occult Blood Test for Colorectal Cancer Screening , 2014, PloS one.
[44] J. Souverijn,et al. Multitarget stool DNA testing for colorectal-cancer screening. , 2014, The New England journal of medicine.
[45] Jian Qi,et al. Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. , 2014, World journal of gastroenterology.
[46] H. Aburatani,et al. Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients , 2014, Cancer medicine.
[47] Bing-sheng Li,et al. Validation of methylation-sensitive high-resolution melting (MS-HRM) for the detection of stool DNA methylation in colorectal neoplasms. , 2014, Clinica chimica acta; international journal of clinical chemistry.
[48] D. Ransohoff,et al. Multitarget stool DNA testing for colorectal-cancer screening. , 2014, The New England journal of medicine.
[49] F. Brunetti,et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer , 2013, BMC Cancer.
[50] Y. Sato,et al. UEG Week 2013 Poster Presentations , 2013, United European Gastroenterology Journal.
[51] A. Papavassiliou,et al. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer , 2013, Journal of Molecular Medicine.
[52] G. Lippi,et al. Epigenetic alteration: new insights moving from tissue to plasma – the example of PCDH10 promoter methylation in colorectal cancer , 2013, British Journal of Cancer.
[53] M. Fraga,et al. DNA Methylation Biomarkers for Noninvasive Diagnosis of Colorectal Cancer , 2013, Cancer Prevention Research.
[54] D. Ahlquist,et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.
[55] Thomas Rösch,et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer , 2013, Gut.
[56] H. Zhang,et al. Detection of Hypermethylated Spastic Paraplegia-20 in Stool Samples of Patients with Colorectal Cancer , 2013, International journal of medical sciences.
[57] A. Goel,et al. Epigenetics of colorectal cancer. , 2012, Gastroenterology.
[58] R. Lamerz,et al. Prognostic role of methylated free circulating DNA in colorectal cancer , 2012, International journal of cancer.
[59] A. Kalmár,et al. Detection of Methylated SEPT9 in Plasma Is a Reliable Screening Method for Both Left- and Right-Sided Colon Cancers , 2012, PloS one.
[60] S. Thibodeau,et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[61] Surbhi Jain,et al. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. , 2012, The Journal of molecular diagnostics : JMD.
[62] Yuanyuan Xie,et al. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China. , 2012, Cancer epidemiology.
[63] K. Kinzler,et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. , 2012, Gastroenterology.
[64] H. Nemoto,et al. Detection of TFPI2 methylation in the serum of colorectal cancer patients. , 2011, Cancer letters.
[65] Alexander Crispin,et al. Methylation of NEUROG1 in Serum Is a Sensitive Marker for the Detection of Early Colorectal Cancer , 2011, The American Journal of Gastroenterology.
[66] T. Fujiwara,et al. Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. , 2011, Acta medica Okayama.
[67] Y. Kodera,et al. p16INK4a methylation in serum as a follow-up marker for recurrence of colorectal cancer. , 2011, Anticancer research.
[68] R. Lothe,et al. SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis , 2011, Oncogene.
[69] Jun Liu,et al. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. , 2011, Clinical and investigative medicine. Medecine clinique et experimentale.
[70] R. Ned,et al. Fecal DNA testing for Colorectal Cancer Screening: the ColoSure™ test , 2011, PLoS currents.
[71] S. Brachs,et al. Fraternal twins: Swiprosin-1/EFhd2 and Swiprosin-2/EFhd1, two homologous EF-hand containing calcium binding adaptor proteins with distinct functions , 2011, Cell Communication and Signaling.
[72] Hua-yun Chen,et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. , 2010, Cancer genetics and cytogenetics.
[73] M. Esteller,et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. , 2010, Clinical colorectal cancer.
[74] Y. Cho,et al. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients. , 2010, Hepato-gastroenterology.
[75] David Sidransky,et al. DNA methylation markers in colorectal cancer , 2010, Cancer and Metastasis Reviews.
[76] Joobae Park,et al. Aberrant Methylation of APC, MGMT, RASSF2A, and Wif-1 Genes in Plasma as a Biomarker for Early Detection of Colorectal Cancer , 2009, Clinical Cancer Research.
[77] N. Matsubara,et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. , 2009, Journal of the National Cancer Institute.
[78] S. Goodman,et al. Sensitive digital quantification of DNA methylation in clinical samples , 2009, Nature Biotechnology.
[79] D. Park,et al. Stool Methylation-Specific Polymerase Chain Reaction Assay for the Detection of Colorectal Neoplasia in Korean Patients , 2009, Diseases of the colon and rectum.
[80] M. Washington,et al. Comparative analysis of PCR-based biomarker assay methods for colorectal polyp detection from fecal DNA. , 2009, Clinical chemistry.
[81] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, PloS one.
[82] J. Herman,et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. , 2009, Journal of the National Cancer Institute.
[83] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.
[84] I. Holen,et al. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[85] J. Herman,et al. GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer , 2009, Clinical Cancer Research.
[86] J. Herman,et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. , 2009, Cancer research.
[87] M. Esteller,et al. Evaluation of stool melting curve analysis of methylated CpG island promoters as an alternative for early noninvasive diagnosis of colorectal tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] J. Millholland,et al. A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection , 2008, The American Journal of Gastroenterology.
[89] B. Leggett,et al. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development , 2008, Genes, chromosomes & cancer.
[90] Ren-Min Zhu,et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. , 2008, World journal of gastroenterology.
[91] G. Sozzi,et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. , 2008, Cancer letters.
[92] Dao-rong Wang,et al. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. , 2008, World journal of gastroenterology.
[93] H. Fiegl,et al. SFRP2 methylation in fecal DNA—a marker for colorectal polyps , 2007, International Journal of Colorectal Disease.
[94] Zhaohui Huang,et al. Hypermethylation of SFRP2 as a Potential Marker for Stool-Based Detection of Colorectal Cancer and Precancerous Lesions , 2007, Digestive Diseases and Sciences.
[95] Fan Yang,et al. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. , 2007, World journal of gastroenterology.
[96] L. Mariani,et al. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. , 2005, Journal of the National Cancer Institute.
[97] L. Myeroff,et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. , 2005, Journal of the National Cancer Institute.
[98] George A. Calin,et al. Frequent Aberrant Methylation of the CDH4 Gene Promoter in Human Colorectal and Gastric Cancer , 2004, Cancer Research.
[99] M. Widschwendter,et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? , 2004, The Lancet.
[100] A. Nakao,et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients , 2003, International journal of cancer.
[101] H. Kuwano,et al. High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. , 2003, Cancer letters.
[102] Hiroshi Nakayama,et al. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. , 2002, Cancer letters.
[103] Dr. med. Hans Leyden. Bericht über die am I. September 1902 in Spanien veranstaltete Krebssammelforschung , 1904, Journal of Cancer Research and Clinical Oncology.
[104] K. El Bairi,et al. Decoding colorectal cancer epigenomics. , 2018, Cancer genetics.
[105] M. Tavallaei,et al. Evaluation of the Epigenetic Biomarker Bone Morphogenic Protein 3 for Colorectal Cancer Diagnosis , 2018 .
[106] K. Ho,et al. An inconvenient truth: our routine imaging pathway for loin pain resulted in superfluous radiation exposure , 2014 .
[107] Abstracts of the 30th German Cancer Congress. February 22-25, 2012. Berlin, Germany. , 2012, Journal of cancer research and clinical oncology.
[108] Y. Yuasa. Epigenetics in molecular epidemiology of cancer a new scope. , 2010, Advances in genetics.
[109] S. Markowitz,et al. Improved fecal DNA test for colorectal cancer screening. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[110] Gerta Rucker,et al. Bmc Medical Research Methodology Open Access the Relationship between Quality of Research and Citation Frequency , 2006 .
[111] T. Anthony,et al. The Effect of Treatment for Colorectal Cancer on Long-Term Health-Related Quality of Life , 2001, Annals of Surgical Oncology.
[112] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.